- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Attention defecit hyperactivity disorder (ADHD)
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Lisdexamfetamine – July 2019
Lisdexamfetamine: Capsule containing lisdexamfetamine dimesilate 20 mg, 40 mg and 60 mg; Vyvanse®
Last updated
1 November 2019